Head-to-head · WeighScore
Primary Clinic (Direct GLP) vs Revel RX
By GLP-1 ScorecardUpdated
Score comparison
Revel RX has the higher recorded score — 77.3/100 to 65.5/100.
Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Primary Clinic (Direct GLP) | Revel RX |
|---|---|---|
| WeighScore | 65.5/100 | 77.3/100 |
| Grade | C | C+ |
| Site position | #245 | #49 |
| Semaglutide | $85/mo (0.25-0.75 mg band, membership required, compounded) | $89/mo (all doses, compounded) |
| Tirzepatide | $133/mo (1.25-2.5 mg band, membership required, compounded) | $155/mo (all doses, compounded) |
| Coverage | 10 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #245 · C
Strengths
- Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
- GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
- Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- Routine labs and thousands of medications included in membership — no surprise bills
- Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
What to consider
- The medication price is on top of an $89/mo direct-primary-care membership, which the FAQ states does not include the drug — all-in is about $174/mo for semaglutide and $222/mo for tirzepatide
- Prices are published as dose BANDS rather than per dose, and the cheapest tirzepatide band starts at 1.25 mg, below the 2.5 mg labeled starting dose
- The pricing is rendered entirely in JavaScript, so nothing on the page is readable without running the site's bundle
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Site position #49 · C+
Strengths
- Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
- LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
- Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
- Free overnight cold shipping included; no hidden fees or dose-based price increases
- Clinical review by MD Integrations, an independent medical group, before any prescription is issued
What to consider
- States served are not publicly listed; eligible states requires completing intake to confirm coverage
- No labs, coaching, or ongoing health support disclosed in any public materials
- Compounded medications are not FDA-approved (site discloses this)
- Newer brand with limited public patient reviews or Trustpilot rating
- Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.